News & Blog

Government regulations, recently announced in the UK, now require Whole Genome Sequencing to be carried out as part of the minimum standards for COVID-19 tests for people arriving in England. In order to support SARS-CoV-2 testing laboratories, we have introduced a Whole Genome Sequencing service.

When Chris Sale and Lee Silcock founded Nonacus in 2015 they had one singular purpose- to develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn't easy. Find out why they went with 'Nonacus'.

This week Nonacus Ltd announced a partnership with Dante Labs and Cambridge Cancer Genomics which aims to build the most comprehensive and patient-centric tumour profiling service enabling improved cancer patient management, treatment and monitoring.

Nonacus was recently awarded an Innovate UK grant to validate novel, rapid surveillance testing for respiratory viral genomes using nanopore sequencing. This method will provide more comprehensive information about the SARS-CoV-2 genome and with a respiratory viral panel in the pipeline, will provide surveillance of other respiratory diseases too.

Nonacus scientists, together with researchers at the University of Cambridge, are working on the development of a novel, non-invasive test for coeliac disease that works even if the patient is already on a gluten-free diet.

Suspected coronavirus patients could be asked to spit into a tube and post the sample to a lab, under plans for a new test being developed by a British firm. Read the interview with Nonacus Ltd in the Sunday Telegraph on how a partnership with Chronomics has led to the development of a spit test for COVID-19.

The impact of the coronavirus is being felt right across the UK and I hope that you, your family and your friends remain safe and well. With yesterday’s announcement from the government, we know that this impact will be wide ranging and may be having a knock on effect on your laboratory. We are hearing of laboratory closures during the self-isolation period and labs operating with a skeleton staff, all of which puts pressure on laboratory services.

Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data. The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.

We are excited to announce that Nonacus are recruiting! Following the successful launch of our Cell3TM DNA product range we are now growing the team and are seeking a highly motivated experienced Quality Assurance (QA) / Quality Control (QC) Production Scientist to join our team. The full job description and details on how to apply...